These findings suggests high expression of Cathepsin H is strongly associated with DR and its subtypes (PDR and diabetic maculopathy), positioning it as a candidate biomarker for diagnosis or disease stratification and suggesting targeted inhibition of Cathepsin H may delay DR progression, particularly for patients with PDR and diabetic maculopathy. Here, CTSH is linked to diabetic maculopathy.